This study is for patient that have been diagnosed with suspected lower respiratory tract infection. The purpose of this study is to evaluate a new test that may be able to find more lung infections than current tests can. This new test is called next-generation sequencing and looks in respiratory secretions for bacteria, viruses, fungi, and other organisms that may cause infection. We hope to learn more about the usefulness of this new test in identifying infections.
This study is for subjects who have been diagnosed with a type of lymph gland disease called Hodgkin Lymphoma which has come back or has not gone away after treatment, including the best treatment known for these diseases. Researchers believe subjects will benefit from an allogeneic (from another human) stem cell transplant which has been offered as a form of treatment for this disease in many other patients. After transplant we will provide a type of medication that targets the CD30+ protein, a protein that is commonly expressed in Hodgkin Lymphoma. This medication is called Brentuximab Vedotin (or Brentuximab). Subjects will be offered treatment with lower doses of chemotherapy drugs, as compared to the higher doses of chemotherapy drugs historically used in transplants for other diseases. This is known as reduced intensity therapy.The main purpose of this study is to determine the safety and outcome of following reduced intensity conditioning and allogeneic stem cell transplantation in selected patients with Hodgkin Lymphoma (specifically CD30+ HL patients) with Brentuximab Vedotin. Subjects can expect to be in this study for 3 years.
This study is for participants who have been diagnosed with cancers of the blood who do not have a related perfect tissue ?match? for BMT. This research is being done to find out if a bone marrow transplant (BMT) from a relative who is not a perfect tissue match is safe and effective in people with cancer. The primary goal of this study is to use chemotherapy and/or radiation therapy to completely get rid of a person?s existing bone marrow, give them new bone marrow from a relative who is not a perfect tissue match, and then give them two doses of additional chemotherapy shortly after receiving the new bone marrow. Participants can expect to be in this study for up to 2 years.
The overall goal of this Community Central Line Infection Prevention (CCLIP) trial is to determine whether use of a promising new intervention, namely 70% isopropyl alcohol embedded protective caps on central lines, in the home setting is associated with a reduction in ambulatory central line-associated bloodstream infections (CLABSI) in a high-risk population of pediatric hematology/oncology patients. This proposed research, working with an anticipated 24 children?s hospitals, will layer a cluster-randomized, cross-over design, clinical trial to standardize and spread best-practice care bundles among caregivers for children with chronic hematologic/oncologic conditions. This proposal will be first prospective trial of a promising new intervention and will focus on the caregivers integral to ambulatory pediatric central line care: patients and families. Successful completion of this project will give healthcare providers, patients, payers, and policymakers generalizable and effective tools for spreading CLABSI eradication efforts outside hospitalized settings.
This clinical trial is being done to collect information about various long-term effects commonly seen in children who survive a stem cell transplant. In particular, information about renal (kidney), cardio-metabolic (heart disease and diabetes) and skeletal (bone) long-term effects will be collected for two years after transplant.
The purpose of this research study is to test the safety, effectiveness and tolerability of an investigational drug called DAS181 on subjects with a very weak immune system who are diagnosed with PIV. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). DAS181 can be administered as a reconstituted dry powder that is breathed into the respiratory tract (nose, throat and lungs) using a liquid aerosol spray administered using a nebulizer. A nebulizer is an electrically powered machine that turns liquid medication into a mist so that it can be breathed directly into the lungs through a face mask or mouthpiece.